This study is a secondary analysis of a clinical trial that evaluated the benefit of exercise on adult cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN) who had completed chemotherapy treatment ( Identifier: NCT02773329). The inclusion criteria were as follows: age 55 years or older; ability to provide written informed consent; diagnosis of current or prior malignancy; completion of chemotherapy; neurotoxic chemotherapy or targeted therapy exposure (agents including platinum-based chemotherapy, vinca alkaloids, taxanes, proteasome inhibitors, and interferons); clinically confirmed CIPN, and ability to walk with or without an assistive device for a minimum of fifteen meters. Participants from the clinical trial with complete daily physical activity (DPA) data were utilized for this secondary analysis. The exclusion criteria included: major known joint problems (e.g., back pain, foot problems such as active ulcers and lower extremities amputation, spinal cord injuries); unstable medical condition or medication that may affect mobility (e.g., use of pain suppressant, or chemotherapy ongoing therapy such as radiotherapy, recent stroke), severe cognitive impairment (e.g., dementia, Parkinson’s disease), and severe uncorrected visual, hearing, or vestibular impairment. Informed consent was obtained from all participants prior to screening. This study was approved by the Baylor College of Medicine Institutional Review Board.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.